12:00 AM
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

IV Brinavess vernakalant regulatory update

CHMP recommended updating the label of Brinavess vernakalant to say that IV anti-arrhythmic medicine (class I and III) should not be given for 4 hours after administration of the mixed channel antagonist. The committee made the recommendation after reviewing a case of severe hypotension and...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >